Razadyne Paragraph IV Certification
This article was originally published in The Pink Sheet Daily
The first ANDA with a Paragraph IV certification for Johnson & Johnson's Alzheimer's product Razadyne (galantamine, formerly Reminyl) was filed Feb. 28, according to FDA's May 3 updated list of filings
You may also be interested in...
The name change for the Alzheimer's product follows reports of medication errors with Sanofi-Aventis' diabetes product Amaryl. J&J agreed to change the name prior to launching the extended-release version of galantamine, which will be available in pharmacies in May.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research